Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: Comparison with aspirin and rosuvastatin

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 1, 2010, Pages 199-205

  Gelosa, Paolo ^a   Ballerio, Rossana ^b   Banfi, Cristina ^b   Nobili, Elena ^b   Gianella, Anita ^b   Pignieri, Alice ^a   Brioschi, Maura ^b   Guerrini, Uliano ^a   Castiglioni, Laura ^a   Blanc Guillemaud, Vanessa ^c   Lerond, Laurence ^c   Tremoli, Elena ^a,b   Sironi, Luigi ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b CENTRO CARDIOLOGICO MONZINO   (Italy)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; ROSUVASTATIN; TERUTROBAN; THROMBOXANE B2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BRAIN DAMAGE; CAROTID ARTERY; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; GENETIC TRANSCRIPTION; HEART PROTECTION; INCIDENCE; MALE; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; SURVIVAL RATE; VASCULARIZATION; VASCULITIS;

ANIMALS; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PRESSURE; BRAIN; ENDOTHELIUM, VASCULAR; FLUOROBENZENES; HYPERTENSION; MAGNETIC RESONANCE IMAGING; MALE; NAPHTHALENES; PROPIONIC ACIDS; PROTECTIVE AGENTS; PYRIMIDINES; RATS; RATS, INBRED SHR; RECEPTORS, PROSTAGLANDIN; RECEPTORS, THROMBOXANE; STROKE; SULFONAMIDES; SURVIVAL ANALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 77953738863     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.165787     Document Type: Article

References (28)

1. Ballerio R, Gianazza E, Mussoni L, Miller I, Gelosa P, Guerrini U, Eberini I, Gemeiner M, Belcredito S, Tremoli E, et al. (2007) Gender differences in endothelial function and inflammatory markers along the occurrence of pathological events in stroke-prone rats. Exp Mol Pathol 82:33-41.
2. Belhassen L, Pelle G, Dubois-Rande JL, and Adnot S (2003) Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 41:1198-1204.
3. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici MG, Mattle HP, Rothwell PM, and PERFORM Study Investigators (2009a) Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovasc Dis 27:509-518.
4. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici M, Mattle HP, Rothwell PM, and PERFORM Study Investigators (2009b) The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. Cerebrovasc Dis 27:608-613.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, and Cohen RA (2000) The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 20:1724-1728. (Pubitemid 30470586)
7. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, and FitzGerald GA (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296:539-541.
8. Cimetière B, Dubuffet T, Muller O, Descombes JJ, Simonet S, Laubie M, Verbeuren TJ, and Lavielle G (1998) Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. Bioorg Med Chem Lett 8:1375-1380. (Pubitemid 28261305)
9. Gelosa P, Nobili E, Gianella A, Blanc-Guillemaud V, Lerond Laurence, Guerrini U, Sironi L, and Tremoli E (2007) S 18886, a thromboxane A2 receptor antagonist, prevents occurrence of spontaneous brain damage in stroke-prone rats via anti-inflammatory activities (Abstract). Cerebrovasc Dis 23:137.
10. Gianella A, Nobili E, Abbate M, Zoja C, Gelosa P, Mussoni L, Bellosta S, Canavesi M, Rottoli D, Guerrini U, et al. (2007) Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol 170:1165-1177.
11. Guerrini U, Sironi L, Tremoli E, Cimino M, Pollo B, Calvio AM, Paoletti R, and Asdente M (2002) New insights into brain damage in stroke-prone rats: a nuclear magnetic imaging study. Stroke 33:825-830.
12. Huang AL and Vita JA (2006) Effects of systemic inflammation on endothelium-dependent vasodilation. Trends Cardiovasc Med 16:15-20.
13. Ishizuka T, Niwa A, Tabuchi M, Nagatani Y, Ooshima K, and Higashino H (2007) Involvement of thromboxane A2 receptor in the cerebrovascular damage of salt-loaded, stroke-prone rats. J Hypertens 25:861-870.
14. Ishizuka T, Niwa A, Tabuchi M, Ooshima K, and Higashino H (2008) Acetylsalicylic acid provides cerebrovascular protection from oxidant damage in salt-loaded stroke-prone rats. Life Sci 82:806-815.
15. Ishizuka T, Sawada S, Sugama K, and Kurita A (2000) Thromboxane A2 (TXA2) receptor blockade suppresses monocyte chemoattractant protein-1 (MCP-1) expression by stimulated vascular endothelial cells. Clin Exp Immunol 120:71-78.
16. Knight S and Johns EJ (2005) Effect of COX inhibitors and NO on renal hemodynamics following ischemia-reperfusion injury in normotensive and hypertensive rats. Am J Physiol Renal Physiol 289:F1072-F1077.
17. Nobili E, Gianella A; Gelosa P, Guerrini U, Blanc-Guillemaud V, Lerond L, Banfi C, Brioschi M, Tremoli E, and Sironi L (2006) Effect of S 18886, a thromboxane A2 receptor antagonist, on the occurrence of spontaneous brain damage in strokeprone rats (abstract). Cerebrovasc Dis 21 (Suppl 4):52.
18. Pleiner J, Schaller G, Mittermayer F, Zorn S, Marsik C, Polterauer S, Kapiotis S, and Wolzt M (2004) Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 110:3349-3354.
19. Qiu LY, Yu J, Zhou Y, and Chen CH (2003) Protective effects and mechanism of action of aspirin on focal cerebral ischemia-reperfusion in rats. Yao Xue Bao 38:561-564.
20. Sebeková K, Eifert T, Klassen A, Heidland A, and Amann K (2007) Renal effects of S18886 (terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes. Diabetes 56:968-974.
21. Sironi L, Gianazza E, Gelosa P, Guerrini U, Nobili E, Gianella A, Cremonesi B, Paoletti R, and Tremoli E (2005) Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol 25:598-603.
22. Sironi L, Tremoli E, Miller I, Guerrini U, Calvio AM, Eberini I, Gemeiner M, Asdente M, Paoletti R, and Gianazza E (2001) Acute-phase proteins before cerebral ischemia in stroke-prone rats: identification by proteomics. Stroke 32:753-760.
23. Viles-Gonzalez JF, Fuster V, Corti R, Valdiviezo C, Hutter R, Corda S, Anand SX, and Badimon JJ (2005) Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition - a magnetic resonance study. Eur Heart J 26:1557-1561.
24. Vita JA, Keaney JF Jr., Larson MG, Keyes MJ, Massaro JM, Lipinska I, Lehman BT, Fan S, Osypiuk E, Wilson PW, Vasan RS, Mitchell GF, and Benjamin EJ (2004) Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation 110:3604-3609.
25. Widlansky ME, Gokce N, Keaney JF Jr, and Vita JA (2003) The clinical implications of endothelial dysfunction. J Am Coll Cardiol 42:1149-1160.
26. Worth NF, Berry CL, Thomas AC, and Campbell JH (2005) S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 183:65-73.
27. Xu S, Jiang B, Maitland KA, Bayat H, Gu J, Nadler JL, Corda S, Lavielle G, Verbeuren TJ, Zuccollo A, et al. (2006) The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 55:110-119.
28. Zuccollo A, Shi C, Mastroianni R, Maitland-Toolan KA, Weisbrod RM, Zang M, Xu S, Jiang B, Oliver-Krasinski JM, Cayatte AJ, et al. (2005) The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 112:3001-3008.